Actin-like 7-beta: Potential Drug Target and Biomarker (G10880)

Target Name: ACTL7B

NCBI ID: G10880

ACTL7B

Actin-like 7-beta: Potential Drug Target and Biomarker

ACTL7B, also known as Actin-like 7-beta (AL7尾), is a protein that is expressed in various tissues and cells in the body. It is a member of the actin family and is involved in a wide range of cellular processes, including cytoskeletal organization, cell adhesion, and signaling pathways. The protein is also known to be a potential drug target and biomarker, which has led to a great deal of interest in its study.

History of the Discovery

The discovery of ACTL7B was made through a combination of biochemical, genetic, and biophysical techniques. The protein was first identified in the 1970s using a technique called affinity purification, which involved using antibodies to capture the protein of interest and then purifying it from the other cellular components. This method was able to identify a protein that was highly specific for the protein target AC7, which is a member of the actin family.

Subsequent studies revealed that ACTL7B was a key component of the cytoskeleton and was involved in the organization of microtubules. This was confirmed by a series of biochemical experiments, including cell fractionation, GFP-fused cells, and biochemical assays. Additionally, genetic studies revealed that ACTL7B was highly conserved across various species and that it was expressed in a wide range of tissues and cells.

Potential Drug Target

The potential drug target for ACTL7B is its role in cell signaling pathways. ACTL7B is involved in several signaling pathways, including the TGF-β pathway and the Wnt/FGF pathway. These pathways are involved in a wide range of cellular processes, including cell growth, differentiation, and survival.

Actinin-like 7-beta has been shown to play a key role in regulating microtubule dynamics and stability, which is important for the proper functioning of the cytoskeleton. Additionally, ACTL7B has been shown to be involved in the regulation of cell adhesion and in the formation of tight junctions, which are important for tissue repair and regeneration.

Biomarker Potential

ACTL7B has also been shown to have potential as a biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. This is because the protein is expressed in a wide range of tissues and cells and is often used as a protein of interest for studies of these diseases.

For example, ACTL7B has been shown to be involved in the regulation of cancer cell growth and has been used as a potential target for anti-cancer drugs. Additionally, ACTL7B has been shown to be involved in the regulation of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. This has led to interest in using ACTL7B as a potential biomarker for these diseases and as a target for therapeutic intervention.

Conclusion

In conclusion, ACTL7B is a protein that is expressed in various tissues and cells in the body and is involved in a wide range of cellular processes, including cytoskeletal organization, cell adhesion, and signaling pathways. Its potential as a drug target and biomarker has led to a great deal of interest in its study and its potential use in the treatment of a wide range of diseases. Further research is needed to fully understand the role of ACTL7B in cellular processes and its potential as a drug target and biomarker.

Protein Name: Actin Like 7B

The "ACTL7B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ACTL7B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets